Migalastat therapy was associated with long-term cardiac remodeling over a 9-year period in a heterozygous woman with Fabry disease and the N224S mutation.
Does migalastat therapy improve long-term cardiac remodeling in a heterozygote woman with Fabry disease?
This case report describes the 9-year cardiac remodeling outcomes of migalastat therapy in a heterozygous female with Fabry disease.
Absolute Event Rate: 0% vs 0%
Fabry disease (FD) is a rare X‑linked lysosomal disorder in which long‑term cardiac outcomes, particularly in heterozygous females, remain incompl...
Tan et al. (Tue,) reported a other. Migalastat therapy was associated with long-term cardiac remodeling over a 9-year period in a heterozygous woman with Fabry disease and the N224S mutation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: